From todays Needham Presentation and their New corporate slides that are on thier Web site.
So now NBIX management talking sometime in 2014 for top Line violet petal study read out vs the more anticipated 1H/14. So I would say Q4/14 is the best we are going to get and knowing this management team and their History of meeting dead lines think early 2015.
Needham webcast clearly says that data readout Q1 2014. You guys are talking about a safety extension to monitor bone loss which is required of all endometriosis drugs. Elagolix shows no evidence of this. Anyway, top line efficacy read out is Q1 2014 according to webcast at Needham this morning.
I have no idea who I am signed in as, but if you are complaining about management and their history of meeting dead lines, you are blaming the wrong person. Abbott-Abbvie has had control of the drug´s progression through the approval process for a long time. While not a fan of KG, it is not his fault.